

## Designed to meet the WHO disablement framework

NeuroCom Systems provide the key functional limitation and impairment information for effectively treating patients with: High risk for falls; Chronic balance problems; Stroke; Parkinson's Disease; Vestibular disorders; and Chronic mobility problems.

The systems provide assessment and rehabilitation protocols, with user-controlled biofeedback for the patient and clinician. The suite of 'daily living assessments' includes age related normative data.

NeuroCom systems are distributed in the UK & Ireland by SLE Ltd and further product and clinical information can be found at the NeuroCom web site at: [www.onbalance.com](http://www.onbalance.com)

If you would like to receive further information, arrange a demonstration or discuss your application please contact SLE Ltd, 232 Seldon Road, South Croydon, Surrey. CR2 6PL.

Tel. 0208 681 1414. Fax. 0208 649 8570.

E-Mail: [sales@sle.co.uk](mailto:sales@sle.co.uk). [www.sle.co.uk](http://www.sle.co.uk)

'Better information leading to better outcomes'.



## Anti-epileptic may provide pain relief in MS



Results from a new study show that the antiepileptic drug Keppra™ (levetiracetam), in combination with tricyclic antidepressants, anticonvulsant drugs and/or long-acting narcotics, provided some multiple sclerosis (MS) patients improvement in pain and uncomfortable sensations associated with their condition. The study was conducted at the MS Treatment and Research Center of the Yale School of Medicine and presented recently at the American Pain Society's 22nd Annual Scientific Meeting.

"We were interested in studying Keppra™ in combination with more commonly used treatments for neuropathic pain and paresthesias in MS patients. Because of its unique mechanism of action, it can potentially complement other anticonvulsant treatments," said Marco Rizzo, MD, PhD, author of the study and assistant professor at the Yale School of Medicine, New Haven, Conn. "We were impressed to find that Keppra™ was well-tolerated and effective for neuropathic pain and uncomfortable numbness."

For further information Tel. UCB Pharma on 01923 211811.

## Largest ever stroke prevention trial



Boehringer Ingelheim recently announced the launch of PRoFESS, the world's largest-ever study in secondary stroke prevention.

PRoFESS (Prevention Regimen For Effectively avoiding Second Strokes) is designed to investigate the potential of ASASANTIN™ RETARD (dipyridamole modified release + aspirin) and MICARDIS™ (telmisartan) to prevent recurrent strokes.

This world-wide multicentre trial will include 16,000 patients in 21 countries. PRoFESS aims to demonstrate that ASASANTIN™ RETARD is superior in preventing recurrent strokes compared with the combination regimen of clopidogrel + aspirin. In addition, MICARDIS™ will be evaluated for effects on stroke risk reduction in hypertensive and non-hypertensive patients. Patient enrolment starts in September 2003 and final results are expected in 2007.

For further information please contact Emma Stafford on 01344 741336 or [stafforde@bra.boehringer-ingelheim.com](mailto:stafforde@bra.boehringer-ingelheim.com)

## The Bereitschaftspotential



Kluwer Academic/Plenum Publishers has published The Bereitschaftspotential: Movement-Related Cortical Potentials edited by Marjan Jahanshahi and Mark Hallett, ISBN 0-306-47407-7. This 328 page book costs EUR 153 / USD\$ 150/ GBP £96.

Kornhuber and Deecke first recorded and reported the Bereitschaftspotential in 1964. This book brings together in a single volume some of the important research on the Bereitschaftspotential and other movement-related cortical potentials. It highlights and addresses some of the pertinent questions relating to the Bereitschaftspotential and identifies the key issues for future investigation.

This book represents a unique compilation of information about the Bereitschaftspotential and related cortical potentials and techniques for measuring preparatory processes in the brain. The book will be of interest to motor physiologists, psychologists and neurologists working in clinical or research laboratories.

For Table of Contents and to order, please see <http://www.wkap.nl/prod/b/0-306-47407-7>

## Didn't win the draw?

Buy Diseases of the Nervous System [2 volume Set]: Clinical Neuroscience and Therapeutic Principles, 3rd Edition, Edited by Arthur Asbury, Guy McKhann, Ian McDonald, Peter Goadsby & Justin McArthur, direct from the publisher.

Current, comprehensive and authoritative, this is the definitive reference for neurologists, neurosurgeons, neuropsychiatrists, and psychiatrists, indeed everyone with a professional or research interest in the neurosciences. Generously illustrated with diagrams, tables, clinical photographs and scans (MRI, fMRI, MRS, SPECT etc) and a colour plate section in each volume - all designed to enhance the readers understanding of the material being presented.

Price for the 2 volume set, ISBN: 0521793513 is £295.00. Order Online at [www.cambridge.org/0521793513](http://www.cambridge.org/0521793513)

For further details contact Cherrill Richardson at: [crichardson@cambridge.org](mailto:crichardson@cambridge.org), Tel: Cambridge University Press on 01223 3256016 .



## Prize draw winners

Congratulations to readers who won the following books in the reader survey prize draw:

### Handbook of Neurological

**Rehabilitation:** Douglas Gentleman, Consultant in Brain Injury Rehabilitation, Centre for Brain Injury Rehabilitation, Dundee; B Concannon, CNS Paediatric Epilepsy, Princess Diana Children's Hospital, Birmingham

### Diseases of the Nervous System:

Zdenek Ambler, Professor of Neurology,

University Hospital Plzen, Czech Republic

### Self Assessment Colour Review of

### Clinical Neurology & Neurosurgery:

Andy Watt, Geriatrics SpR, Victoria Infirmary, Glasgow; Rustam Al-Shammi, SpR Neurology, Western General Hospital, Edinburgh

### Current Practice of Clinical

**Electroencephalography:** P Ray, SpR, QE Neuroscience Centre, Birmingham

On hearing that he had won Diseases of the Nervous System, Professor Ambler said, "I am really very much looking forward to receiving a copy of this book. It will be a much appreciated addition to our library".

Thank you to everyone who completed our reader survey.